Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

Cited by (723)

Items 101–200 of 723

1. Turning cold tumors into hot tumors to ignite immunotherapy
   Yuan‐Tong Liu, Yunlong Wang, Shuo Wang, Jiajun Li, Wei A. He, Xin-Juan Fan, Xiang‐Bo Wan · 2025 · Molecular Cancer
2. Immunobiology of T Cells in Sjögren’s Syndrome
   Yuan Yao, Jin-Fen Ma, Christopher Chia-Chi Chang, Ting Xu, Cai‐Yue Gao, Merrill Eric Gershwin, Zhe‐Xiong Lian · 2020 · Clinical Reviews in Allergy & Immunology
3. Decoding immunogenic cell death from a dendritic cell perspective
   Sophie Janssens, Sofie Rennen, Patrizia Agostinis · 2023 · Immunological Reviews
4. Epigenetic state determines the in vivo efficacy of STING agonist therapy
   Falahat, Rana, Berglund, Anders, Perez-Villarroel, Patricio, Putney, Ryan M., Hamaidi, Imene, Kim, Sungjune, Pilon-Thomas, Shari, Barber, Glen N., Mulé, James J. · 2023 · Nature Communications
5. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8 + T cell-mediated antitumour immunity and improves anti-PD-1 efficacy
   Ning Cai, Kun Cheng, Yue Ma, Sha Liu, Ran Tao, Yani Li, Danfeng Li, Bin Guo, Wenlong Jia, Huifang Liang et al. · 2023 · Gut
6. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC)
   Yihe Yan, Leting Zheng, Qiang Du, Hamza O. Yazdani, Kun Dong, Yarong Guo, David A. Geller · 2021 · Cancer Letters
7. Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma
   Hyun-Jin Kim, Jang Hyun Park, Hyeon Cheol Kim, Chae Won Kim, In Kang, Heung Kyu Lee · 2022 · Nature Communications
8. Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
   Qiqun Zeng, Sadegh Saghafinia, Agnieszka Chryplewicz, Nadine Fournier, Lucine Christe, Yuqing Xie, Jérémy Guillot, Simge Yucel, Pumin Li, José A. Galván et al. · 2022 · Science
9. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer
   Daniiar Dyikanov, Aleksandr Zaitsev, Т.В. Васильева, Iris Wang, Arseniy A. Sokolov, Evgenii S Bolshakov, Alena Frank, Polina Turova, Olga Golubeva, Anna Gantseva et al. · 2024 · Cancer Cell
10. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice
    Shilong Zhang, Bing Han, Yuqin Mao, Zhengyan Zhang, Zhanming Li, Chao‐Yue Kong, You Wu, Guoqiang Chen, Li‐Shun Wang · 2022 · Gut Microbes
11. Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy
    Giulia Escobar, Katherine Tooley, Joan Pagès Oliveras, Linglin Huang, Hanning Cheng, Michelle L. Bookstaver, Camilla Edwards, Eugene Froimchuk, Chang Xue, Davide Mangani et al. · 2023 · Cancer Cell
12. Immune responses in checkpoint myocarditis across heart, blood and tumour
    Steven Michael Blum, Daniel A. Zlotoff, Neal Patrick Smith, Isabela Kernin, Swetha Ramesh, Leyre Zubiri, Joshua Caplin, Nandini Samanta, Sidney Martin, Mike Wang et al. · 2024 · Nature
13. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
    Siqi Li, Kun Li, Kang Wang, Haoyuan Yu, Xiang‐Yang Wang, Mengchen Shi, Zhixing Liang, Yang Zhou, Yongwei Hu, Yang Li et al. · 2023 · Nature Communications
14. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
    Molly Fisher Thomas, Kamil Slowikowski, Kasidet Manakongtreecheep, Pritha Sen, Nandini Samanta, Jessica Tantivit, Mazen Nasrallah, Leyre Zubiri, Neal Patrick Smith, Alice J. Tirard et al. · 2024 · Nature Medicine
15. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
    Allison A. Fitzgerald, Shangzi Wang, Veena R. Agarwal, Emily F. Davis-Marcisak, Annie Zuo, Sandra A. Jablonski, Melanie Loth, Elana Judith Fertig, John R. MacDougall, Eugene A. Zhukovsky et al. · 2021 · Journal for ImmunoTherapy of Cancer
16. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity
    Longchao Liu, Jiahui Chen, Hongyi Zhang, Jianfeng Ye, Casey Moore, Changzheng Lu, Yan Fang, Yang‐Xin Fu, Bo Li · 2022 · Nature Cancer
17. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
    Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker Martin Lauschke, Isabel Barragán · 2020 · Journal of Clinical Medicine
18. Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy
    Bo He, Anna Johansson, Joseph Backhouse, Ji Li, Gabriel Lee, Juliana Hamzah, Ruth Ganß · 2020 · Cell Reports
19. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
    Qianmei Yang, Gang Shi, Xiaolei Chen, Yi Lin, Lin Cheng, Qingyuan Jiang, Xi Yan, Ming Jiang, Yiming Li, Hantao Zhang et al. · 2020 · Theranostics
20. Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
    Vidit Bhandarkar, Teresa Dinter, Stefani Spranger · 2025 · Science Immunology
21. Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma
    Tao Yang, Yuki Mochida, Xueying Liu, Hang Zhou, Jinbing Xie, Yasutaka Anraku, Hiroaki Kinoh, Horacio Cabral, Kazunori Kataoka · 2021 · Nature Biomedical Engineering
22. CXCR3-CXCL9: It’s All in the Tumor
    Étienne Humblin, Alice Oliffson Kamphorst · 2019 · Immunity
23. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
    Sylvain Simon, Valentin Voillet, Virginie Vignard, Zhong Wu, Camille Dabrowski, Nicolas Jouand, Tiffany Beauvais, Amir Khammari, Cécile Braudeau, Régis Josien et al. · 2020 · Journal for ImmunoTherapy of Cancer
24. Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
    Yan Qu, Ji Wen, Graham D. Thomas, Wenjing Yang, Weiwei Prior, Wenqian He, Purnima Desai Sundar, Xiao Wang, Shobha Potluri, Shahram Salek‐Ardakani · 2020 · Cell Reports
25. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
    Stefanie Seitz, Tobias F. Dreyer, Christoph Stange, Katja Steiger, Rosalinde Bräuer, Leandra Scheutz, Gabriele Multhoff, Wilko Weichert, Marion B. Kiechle, Viktor Magdolen et al. · 2022 · British Journal of Cancer
26. Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
    Lisa Haas, Anna C. Obenauf · 2019 · Frontiers in Immunology
27. The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies
    Heidi Braumüller, Bernhard Mauerer, Johanna Andris, Christopher Berlin, Thomas Wieder, Rebecca Kesselring · 2022 · Cells
28. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells
    Étienne Humblin, Isabel Korpas, Jiahua Lu, Dan Filipescu, Verena van der Heide, Simon Goldstein, Abishek Balachandra Vaidya, Alessandra Soares Schanoski, Beatrice Casati, Myvizhi Esai Selvan et al. · 2023 · Science Immunology
29. CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
    Biao Zhang, Jinming Liu, Yuying Mo, Kexin Zhang, Bingqian Huang, Dong Shang · 2024 · Frontiers in Immunology
30. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
    Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montané, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst et al. · 2024 · Science Translational Medicine
31. Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq
    Santiago J. Carmona, Imran Siddiqui, Mariia Bilous, Werner Held, David Gfeller · 2020 · OncoImmunology
32. Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
    Melinda L. Telli, Hiroshi Nagata, Irene Wapnir, Chaitanya R. Acharya, Kaitlin Zablotsky, Bernard A. Fox, Carlo Bruno Bifulco, Shawn M. Jensen, Carmen Ballesteros‐Merino, Mai Hope Le et al. · 2021 · Clinical Cancer Research
33. Role of CXCR3 signaling in response to anti-PD-1 therapy
    Xiao Han, Ying Wang, Jing Sun, Tao Tan, Xiaomin Cai, Peinan Lin, Yang Tan, Bingfeng Zheng, Biao Wang, Jiawei Wang et al. · 2019 · EBioMedicine
34. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration
    Hussein Sultan, Juan Wu, Valentyna I. Fesenkova, Aaron E. Fan, Diane Addis, Andres Μ. Salazar, Esteban Celis · 2020 · Journal for ImmunoTherapy of Cancer
35. EMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion
    Qun Chen, Jing Jin, Xin Huang, Fan Wu, Hongguang Huang, Renya Zhan · 2021 · Journal of Experimental & Clinical Cancer Research
36. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10
    Mu‐Yang Huang, Yu‐Chi Chen, Wen-Yu Lyu, Xinyu He, Zi-Han Ye, Can-Yu Huang, Xinling He, Xiuping Chen, Xiaobing Chen, Baoxian Zhang et al. · 2023 · Pharmacological Research
37. mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment
    Michael Haas, Michael H. Kagey, Heidi Heath, Franziska Schuerpf, James B. Rottman, Walter Newman · 2020 · Molecular Cancer Research
38. Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal
    Fang Hong, Qianqian Meng, Weiyu Zhang, Ruiqin Zheng, Xiaoyun Li, Tao Cheng, Deqing Hu, Xin Gao · 2021 · Cancer Immunology Research
39. Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications
    Annalisa Del Prete, Francesca Sozio, Ilaria Barbazza, Valentina Salvi, Laura Tiberio, Mattia Laffranchi, Angela Gismondi, Daniela Bosisio, Tiziana Schioppa, Silvano Sozzani · 2020 · International Journal of Molecular Sciences
40. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
    Xiaoyi Jiang, Jian Wang, Xichen Zheng, Zhida Liu, Xinyu Zhang, Yuwei Li, Jonathan Wilhelm, Jun Cao, Gang Huang, Jinlan Zhang et al. · 2022 · Journal for ImmunoTherapy of Cancer
41. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
    Lelliott, Emily J., McArthur, Grant A., Oliaro, Jane, Sheppard, Karen E. · 2021 · Frontiers in Immunology
42. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment
    Binbin Cheng, Wei Wang, Xiaoge Niu, Yichang Ren, Ting Liu, Hao Cao, Shuanghu Wang, Yingfeng Tu, Jingxuan Chen, Shuwen Liu et al. · 2020 · Journal of Medicinal Chemistry
43. Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
    Yan Qu, Ji Wen, Graham D. Thomas, Wenjing Yang, Weiwei Prior, Wenqian He, Purnima Desai Sundar, Xiao Wang, Shobha Potluri, Shahram Salek‐Ardakani · 2020 · Cell Reports
44. A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
    Santiago Sánchez‐Alonso, Giulia Setti-Jerez, Montserrat Arroyo, Tathiana Hernández, Ma Inmaculada Martos, J.M. Sánchez-Torres, Rámón Colomer, Almudena R. Ramiro, Arántzazu Alfranca · 2020 · Journal for ImmunoTherapy of Cancer
45. The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
    Chae Won Kim, Kyun‐Do Kim, Heung Kyu Lee · 2021 · BMB Reports
46. Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
    Cunqing Kong, Banghao Xu, Guanhua Qiu, Meng Wei, Mengqi Zhang, Shengxian Bao, Jiali Tang, Lequn Li, Junjie Liu · 2022 · International Journal of Nanomedicine
47. Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
    Jannie G. Borst, Julia Busselaar, Douwe M. T. Bosma, FERRY A. OSSENDORP · 2021 · European Journal of Immunology
48. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
    Kristian Michael Hargadon · 2020 · Clinical and Translational Medicine
49. CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape
    Yatong Chen, Jing Xu, Xiaodong Wu, Hui Yao, Zhou Yan, Ting Guo, Wenjing Wang, Peixiao Wang, Yu Li, Xiang-Min Yang et al. · 2020 · Cellular and Molecular Immunology
50. CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer
    Yuanke Liang, Ze-kun- Deng, Mu-tong CHEN, Si-Qi Qiu, Yingsheng Xiao, Yuzhu Qi, Qin Xie, Zheng-hao Wang, Shicheng Jia, De Zeng et al. · 2021 · Frontiers in Oncology
51. Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength
    Thomas A.E. Elliot, Emma K. Jennings, David A.J. Lecky, Natasha Thawait, Adriana Flores‐Langarica, Alastair Copland, Kendle M. Maslowski, David Cameron Wraith, David Bending · 2021 · Immunity
52. Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy
    Kun Wang, Sushant Patkar, Joo Sang Lee, E. Michael Gertz, Welles Robinson, Fiorella Schischlik, David R. Crawford, Alejandro A. Schäffer, Eytan Ruppin · 2022 · Cancer Discovery
53. Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity
    Minjie Pan, Xiao‐Shan Wei, Xuan Xiang, Yanhong Liu, Qiong Zhou, Wei-Bing Yang · 2023 · Clinical & Translational Oncology
54. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade
    Ivy X. Chen, Kathleen Newcomer, Kristen E. Pauken, Vikram R. Juneja, Kamila Naxerova, Michelle W. Wu, Matthias Pinter, Debattama R. Sen, Meromit Singer, Arlene H. Sharpe et al. · 2020 · Proceedings of the National Academy of Sciences
55. Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
    Eleonora Russo, Angela Santoni, Giovanni Bernardini · 2020 · Journal of Leukocyte Biology
56. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization
    Alycia Gardner, Álvaro de Mingo Pulido, Kay Hänggi, Sarah Bazargan, Alexis Onimus, Agnieszka Kasprzak, Jose Ramon Conejo-Garcia, Katarzyna Anna Rejniak, Brian Ruffell · 2022 · Journal for ImmunoTherapy of Cancer
57. HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells
    Lili Li, Shumin Hao, Meiling Gao, Junxiao Liu, Xin Xu, Jianfei Huang, Genhong Cheng, Heng Yang · 2023 · Cancer Immunology Research
58. Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
    Nicolas Roussot, François Ghiringhelli, Cédric Rébé · 2022 · Cells
59. Lymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
    Sharanya K M Wijesinghe, Lisa Rausch, Sarah S. Gabriel, Giovanni Galletti, Marco De Luca, Qin L, Lifen Wen, Carlson Tsui, Kevin Man, Leonie Heyden et al. · 2025 · Nature Immunology
60. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity
    Caleb R. Stoltzfus, Ramya Sivakumar, Leo Kunz, Brandy E. Olin, Elena Menietti, Dario Speziale, Roberto Adelfio, Marina Bacac, Sara Colombetti, Mario Perro et al. · 2021 · Frontiers in Immunology
61. CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy
    Yonggui Tian, Chunli Wen, Zhen Zhang, Yanfen Liu, Feng Li, Qitai Zhao, Chang Yao, Kaiyuan Ni, Shengli Yang, Yi Zhang · 2022 · Cancer Immunology Immunotherapy
62. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Antje Tunger, Ulrich J. Sommer, Rebekka Wehner, Anne Sophie Kubasch, Marc‐Oliver Grimm, Michael Philipp Bachmann, Uwe Platzbecker, Martin Bornhäuser, Gustavo Bruno Baretton, Marc Schmitz · 2019 · Journal of Clinical Medicine
63. Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle
    Max Miller Wattenberg, Gregory Lawrence Beatty · 2020 · Seminars in Cancer Biology
64. Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy
    Katherine M. Audsley, Alison M. McDonnell, Jason C. Waithman · 2020 · Cells
65. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
    Zoe C. Schmiechen, Ingunn M. Stromnes · 2021 · Frontiers in Immunology
66. Tumor‐associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevance
    Ioana Plesca, Luise Müller, Jan P. Böttcher, Hind Medyouf, Rebekka Wehner, Marc Schmitz · 2022 · European Journal of Immunology
67. The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment
    Shiyong Neo, Andreas Lundqvist · 2020 · Advances in experimental medicine and biology
68. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
    Ann Willman Silk, Steven J O'Day, Howard L. Kaufman, Jennifer Bryan, Jacqueline Norrell, Casey M. Imbergamo, Daniella E. Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Seymour H. Fein et al. · 2022 · Cancer Immunology Immunotherapy
69. The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cell homing to bone
    Subhashis Pal, Daniel S. Perrien, Tetsuya Yumoto, Roberta Faccio, Andreea Stoica, Jonathan Adams, Craig M. Coopersmith, Rheinallt M. Jones, M. Neale Weitzmann, Roberto Pacifici · 2022 · Journal of Clinical Investigation
70. The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
    Yize Mao, Hui Xie, Min‐Yi Lv, Qiuxia Yang, Zeyu Shuang, Feng Gao, Shengping Li, Lina Zhu, Wei Wang · 2023 · Cancer Immunology Immunotherapy
71. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
    Natasa Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann et al. · 2021 · Journal for ImmunoTherapy of Cancer
72. Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines
    Laia Gorchs, Helen Kaipe · 2021 · Cancers
73. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
    Vera Petrova, Ihor Arkhypov, Rebekka Weber, Christopher Groth, Peter Altevogt, Jochen Sven Utikal, Viktor Umansky · 2020 · International Journal of Molecular Sciences
74. β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer
    Caihong Wang, Jingjing Yan, Pan Yin, Liming Gui, Lu Ji, Bin Ma, Wei‐Qiang Gao · 2020 · OncoImmunology
75. The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer
    Beatriz Subtil, Alessandra Cambi, Daniele V. F. Tauriello, I. Jolanda M. de Vries · 2021 · Frontiers in Immunology
76. CAR T-cells for colorectal cancer immunotherapy: Ready to go?
    Bouchra Ghazi, Adil El Ghanmi, Sarah Kandoussi, Amina Ghouzlani, Abdallah Badou · 2022 · Frontiers in Immunology
77. Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice
    Zhenzhen Wen, Tong Liu, Xutao Xu, Nandini Acharya, Zhida Shen, Yunkun Lu, Junjie Xu, Ke Guo, Shuying Shen, Yuening Zhao et al. · 2025 · Nature Communications
78. Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets
    Robin Reschke, Alexander Heinrich Enk, Jessica C. Hassel · 2024 · International Journal of Molecular Sciences
79. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer
    Tino Vollmer, Stephan Schlickeiser, Leila Amini, Sarah Schulenberg, Désirée J. Wendering, Viqar Showkat Banday, Anke Jurisch, Rebecca Noster, Désirée Kunkel, Nicola R. Brindle et al. · 2021 · Science Translational Medicine
80. CXCR3 regulates stem and proliferative CD8+ T cells during chronic infection by promoting interactions with DCs in splenic bridging channels
    Derek J. Bangs, Alexandra Tsitsiklis, Zoë Steier, Shiao Wei Chan, James Kaminski, Aaron Streets, Nir Yosef, Ellen A. Robey · 2022 · Cell Reports
81. Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
    Elizabeth C. Eckert, Rebecca A. Nace, Jason M. Tonne, Laura Evgin, Richard G. Vile, Stephen J. Russell · 2019 · Molecular Therapy — Oncolytics
82. M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
    Rui Zhao, Qianyi Wan, Yong Wang, Yutao Wu, Shuomeng Xiao, Qiqi Li, Xiaoding Shen, Wen Zhuang, Yong Zhou, Lin Xia et al. · 2020 · OncoImmunology
83. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
    Sonja Vukadin, Farah Khaznadar, Tomislav Kizivat, Aleksandar Včev, Martina Smolić · 2021 · Biomedicines
84. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models
    Robert J. Torphy, Yi Sun, Ronggui Lin, Alayna K. Caffrey-Carr, Yuki Fujiwara, Felix Ho, Emily N. Miller, Martin D. McCarter, Traci Renae Lyons, Richard David Schulick et al. · 2022 · Nature Communications
85. Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors
    José Gabriel Barcia Durán, Dayasagar Das, Michael A. Gildea, Letizia Amadori, Morgane Gourvest, Ravneet Kaur, Natalia Eberhardt, Panagiotis Smyrnis, Burak Cılhoroz, Swathy Sajja et al. · 2024 · Nature Cardiovascular Research
86. DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps
    Degao Chen, Zheng Jin, Chu Han, Yucui Wu, Yangping Bian, Ting Yuan, Hao Lv, Qiuyu Xia, Lei Wang, Qian Chu et al. · 2025 · Cancer Cell
87. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
    Holger Bronger, Viktor Magdolen, Peter Goettig, Tobias F. Dreyer · 2019 · Cancer and Metastasis Reviews
88. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
    Sara Santana-Hernández, Jesús Suárez-Olmos, Sònia Servitja, Pau Berenguer‐Molins, Marcel Costa-García, Laura Comerma, Anna Rea, Júlia Perera‐Bel, Sílvia Menéndez, Oriol Arpí et al. · 2024 · Journal of Experimental & Clinical Cancer Research
89. Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis
    Jintao Xu, Lori M. Neal, Anutosh Ganguly, Jessica L. Kolbe, Jessica C. Hargarten, Waleed Abdel Wahab Elsegeiny, Christopher Hollingsworth, Xiumiao He, Mike Ivey, Rafael Lopez et al. · 2020 · Science Advances
90. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
    Shravan Leonard‐Murali, Chetana Bhaskarla, Ghanshyam Singh Yadav, Sudeep K. Maurya, Chenna R. Galiveti, Joshua A. Tobin, Rachel J. Kann, Eishan Ashwat, Patrick S. Murphy, Anish Bhaswanth Chakka et al. · 2024 · Nature Communications
91. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia
    Francesco Mazziotta, Luca Biavati, Joseph C. Rimando, Sergio Rutella, Nicholas C. Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent et al. · 2024 · Blood
92. Dendritic cell subsets and implications for cancer immunotherapy
    Michael Y. Chen, Felicia Zhang, Simon Peter Goedegebuure, William E. Gillanders · 2024 · Frontiers in Immunology
93. CRISPR screen in mechanism and target discovery for cancer immunotherapy
    Dan Liu, Xuan Zhao, Anqun Tang, Xiyue Xu, Shuci Liu, Li Zha, Wen Ma, Junnian Zheng, Ming Shi · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
94. CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner
    M.M. Leblond, Laure Tillé, Sina Nassiri, Connie B. Gilfillan, Claire Imbratta, Martina Schmittnaegel, Carola Hermine Ries, Daniel E. Speiser, Grégory Verdeil · 2020 · Cancer Immunology Research
95. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment
    Xuchao Yang, Binbin Cheng, Yao Xiao, Mingming Xue, Ting Liu, Hao Cao, Jianjun Chen · 2020 · European Journal of Medicinal Chemistry
96. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities
    Ganesan Ramamoorthi, Krithika Nandakumar Kodumudi, Corey Gallen, Nadia Nocera Zachariah, Amrita B Basu, Gabriella K. Albert, Amber Beyer, Colin Snyder, Doris A. Wiener, Ricardo Lima Barros Costa et al. · 2021 · Seminars in Cancer Biology
97. Dendritic cells maintain anti-tumor immunity by positioning CD8 skin-resident memory T cells
    Jennifer L. Vella, Aleksey K. Molodtsov, Christina Vadala Angeles, Bruce R. Branchini, Mary Jo Turk, Yina H. Huang · 2021 · Life Science Alliance
98. Radiotherapy enhances CXCR3highCD8+ T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells
    Chih‐Liang Wang, Ai‐Sheng Ho, Chun‐Chao Chang, Zong‐Lin Sie, Cheng‐Liang Peng, Jungshan Chang, Chun‐Chia Cheng · 2023 · Cancer Immunology Immunotherapy
99. Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
    Michael B. Ware, Maggie Phillips, Christopher William McQuinn, Mohammad Y. Zaidi, Hannah M. Knochelmann, Emily R. Greene, Brian Scott Robinson, Cameron J. Herting, Thomas A. Mace, Zhengjia Chen et al. · 2023 · JCI Insight
100. Structural insights into the activation and inhibition of CXC chemokine receptor 3
     Haizhan Jiao, Bin Pang, Aijun Liu, Qiang Chen, Qi Pan, Xiankun Wang, Yunong Xu, Ying‐Chih Chiang, Ruobing Ren, Hongli Hu · 2024 · Nature Structural & Molecular Biology